Compare WH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WH | PCVX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.1B |
| IPO Year | 2017 | 2020 |
| Metric | WH | PCVX |
|---|---|---|
| Price | $74.97 | $57.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $93.46 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-21-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $1,429,000,000.00 | N/A |
| Revenue This Year | $6.44 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $29.86 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $69.21 | $28.09 |
| 52 Week High | $93.58 | $76.61 |
| Indicator | WH | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 50.93 |
| Support Level | $70.51 | $42.30 |
| Resistance Level | $75.01 | $65.00 |
| Average True Range (ATR) | 2.73 | 3.01 |
| MACD | -1.06 | -0.60 |
| Stochastic Oscillator | 9.63 | 19.89 |
As of June 30, 2025, Wyndham Hotels & Resorts operates 846,700 rooms across more than 20 brands predominantly in the economy and midscale segments. Super 8 is the largest brand, representing around 18% of all rooms, with Days Inn (13%) and Ramada (14%) the next two largest brands, as of the end of 2024. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represents 56% of total rooms, as of the end of 2024.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.